© 2018 LabShares Newton LLC

Upcoming Events

Lunch@LabShares are events intended for the benefit of our members, though we hold five spots for non-members wishing to attend. If you are a non-member, please email hannah@labshares to reserve a spot.


Stay up to date on news concerning LabShares, our members and the Boston Biotech industry!

LabShares News

March 13, 2019

LabShares is unveiling a major rennovation

LabShares Newton Grows its Business​

November 2, 2018

A new office and laboratory incubator for emerging biotechnology and life science companies has just opened in Newton’s Charles River Mill District.

Life Sciences Co-Working Incubator LabShares Launches in Newton

November 14, 2018

The next groundbreaking medical discovery could be made right here in the city, as companies conduct research and experiments at LabShares Newton, an “incubator lab” on Bridge Street that is in the process of expanding.

Science incubator LabShares Newton is Set to Expand

November 2, 2018

Longtime biotech executive Jeff Behrens ventured out of the C-Suite earlier this year, opening the first life sciences-focused incubator in Newton. Now he's expanding the project amid broader demand for shared lab space.

Newton's First Life Sciences Incubator Set  To Expand
Member News
Screenshot 2019-03-13 09.28.12.png

August 19, 2019

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialize antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform. 

Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
0041_8786 copy.jpg

April 14, 2019

One of the dominating players in the 3D Printed Drugs market is Extend Biosciences

Global 3D Printed Drugs Market Insights 2019-2024 : Extend Biosciences, Bioduro, Affinity Therapeutics
Screenshot 2019-04-08 15.58.24.png

August 8, 2018

USA-based Harbour BioMed has entered into an exclusive strategic partnership with China’s Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize A167

Harbour BioMed inks $350 million deal for rights to A167
Screenshot 2019-04-08 15.58.24.png

June 12, 2019

The MoU was signed during the official, 40thanniversary celebration ceremony of the Shanghai-Rotterdam Sister City Relationship.

Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development
abcuro logo.jpeg

March 26, 2019

First in vivo validation of KLRG1 as a new cancer immunotherapy target

Abcuro announces pre-clinical data on new immuno-oncology target
Press Releases

May 9, 2019

Second Launch@Shares Competition Announced in Collaboration with MTTC/MALSI Conference and MassBio’s MassCONNECT Program

LabShares Newton Selects Savran Technologies as Winner of First Launch@LabShares Competition Valued at $50K

October 31, 2018

LabShares Newton, an office and laboratory incubator for emerging biotechnology and life science companies, announced the launch of its first location in Newton.

LabShares Newton Launches Near Capacity and Announces Expansion Plans

March 13, 2019

LabShares Newton's newly expanded facility features a cutting-edge lab and co-working space that can now accommodate up to 30 startups

LabShares Celebrates Grand Opening and Unveils Newly Expanded Shared Office and Lab Space in Newton
Past Newsletters